- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00933894
VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram
16 dicembre 2010 aggiornato da: Tibotec BVBA
A Phase I, Open-label, Randomized, Crossover Trial in 16 Healthy Subjects to Investigate the Potential Pharmacokinetic Interaction Between Telaprevir and Escitalopram at Steady-state
The purpose of this study is to investigate the effect of steady-state telaprevir (TVR) 750 mg q8h (3 times a day, every 8 hours) on the steady-state pharmacokinetics of escitalopram 10 mg q.d.
(once a day), and vice versa.
Steady state is a term which means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose.
TVR is being investigated for the treatment of chronic hepatitis C virus (HCV) infection.
Pharmacokinetics (pk) means how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body.
Panoramica dello studio
Descrizione dettagliata
Telaprevir is being investigated for treatment of chronic HCV infection, in combination with Peg-IFN (pegylated interferon) and RBV (ribavirin).
Peg-IFN plus RBV are currently an accepted methode for treating HCV.
Treatment with Peg-IFN plus RBV for HCV infection is associated with a high rate of depression.
The results of this study will provide dosing recommendations for coadministration of Telaprevir (TVR) and escitalopram in HCV-infected patients.
This is a Phase I, open-label (both participant and investigator know the name of the medication), randomized (study medication assigned by chance), crossover trial in 16 healthy participants to investigate the pharmacokinetic interaction between escitalopram and TVR, both at steady state.
Steady state is a term which means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose.
The participants will receive two treatments (treatment A-B or treatment B-A) in a randomized order.
In Treatment A, participants will receive escitalopram 10 mg once daily (q.d.) for 7 days.
In Treatment B, participants will receive TVR 750 mg every 8 hours (q8h) for 14 days, with coadministration of escitalopram 10 mg q.d.
from Day 8 to Day 14.
There will be a washout period (a period where no treatment will be taken in view of having all the medication eliminated from the body before starting a new treatment) of at least 14 days between last intake of study medication in one session and first intake of study medication in the subsequent session.
All study medication will be taken with food.
Escitalopram will be taken once daily in the morning.
During coadministration of TVR and escitalopram, the first dose of TVR should be taken together with escitalopram in the morning.
Pharmacokinetic profiles of the two compounds will be measured through blood samples taken at regular intervals during the study and safety and tolerability will be assessed during the study period and in follow-up.
Safety and tolerability evaluations will be recorded at regular intervals throughout the trial period.
Blood and urine samples, electrocardiogram (ECG) and vital signs (blood pressure and hart rate) will be taken at screening, before medication intake on days 1 and 7 in each session and on day 14 in treatment B and at the 2 follow up visits at 5-7 and 30-32 days after last dose of drug in the last session.
A physical examination will be performed at screening, on day before first medication intake in each session and during the 2 follow up visits.
Participants in Treatment A will receive oral escitalopram 10 mg once daily for 7 days and in Treatment B participants will receive TVR 750 mg q8h from Day 1 to Day 14, with coadministration of escitalopram 10 mg q.d.
from Day 8 to Day 14.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
16
Fase
- Fase 1
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
Da 18 anni a 55 anni (Adulto)
Accetta volontari sani
Sì
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Females should be post-menopausal for at least 2 years (amenorrheal for at least 3 years), or have undergone tubal ligation (or other permanent birth control methods), or hysterectomy (total), or oophorectomy (bilateral), and should not be breastfeeding
- Nonsmoking or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months before study screening
- Body mass index (BMI, weight in kg divided by the square of height in meters) of 18 to 30 kg/m2, extremes included, at study screening
- normal 12-lead ECG at screening
- Healthy on the basis of a physical examination, medical history, vital signs, and the results of blood chemistry, hematological and coagulation tests and urinalysis carried out at screening
Exclusion Criteria:
- Participants should stop any short-duration courses of prescription medication at least 14 days before first intake of study medication, potential participants should not stop any chronic, prescribed medication being taken at the direction of a physician, without obtaining agreement from that physician
- Participants should stop over-the-counter medications on the date of the screening visit but no less than 7 days prior to the first administration of study medication, potential participants should not stop any chronic, over-the-counter medication being taken at the direction of a physician, without obtaining agreement from that physician
- Consumption of more than 2 units of alcoholic beverages per day or more than 14 units per week (1 unit of alcohol equals 1 glass [285 mL] of beer, 1 glass [125 mL] of wine, 25 mL shot of 40% spirit) from 14 days before the first intake of study medication until completion of the pharmacokinetic sampling in the last treatment session
- Participants may not consume any alcohol 72 hours before or after study drug administration
- Positive test for any of the following infectious disease tests: hepatitis A infection (confirmed by hepatitis A antibody IgM), hepatitis B antigen (HBsAg), hepatitis C virus antibody (HCVAb), human immunodeficiency virus 1 antibody (HIV1Ab), or human immunodeficiency virus 2 antibody (HIV2Ab)
- Male participants with female partners that are planning to become pregnant during the study or within 90 days of the last dose of study medication
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Nessuno (etichetta aperta)
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
To investigate the effect at steady-state of TVR 750 mg q8h on the steady-state pharmacokinetics of escitalopram 10 mg q.d. in healthy participants and vica versa.
Lasso di tempo: pk profiles of TVR will be measured up to 8 hours after intake of the morning dose on Day 7 and 14 of Treatment B. Pharmacokinetic profiles of escitalopram will be measured up to 24 hours postdose on Day 7of Treatment A and Day 14 of Treatment B.
|
pk profiles of TVR will be measured up to 8 hours after intake of the morning dose on Day 7 and 14 of Treatment B. Pharmacokinetic profiles of escitalopram will be measured up to 24 hours postdose on Day 7of Treatment A and Day 14 of Treatment B.
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
The short-term safety and tolerability of coadministration of TVR and escitalopram in healthy participants
Lasso di tempo: This will be determined throughout the study; at all study visits
|
This will be determined throughout the study; at all study visits
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 settembre 2009
Completamento primario (Effettivo)
1 novembre 2009
Completamento dello studio (Effettivo)
1 novembre 2009
Date di iscrizione allo studio
Primo inviato
2 luglio 2009
Primo inviato che soddisfa i criteri di controllo qualità
2 luglio 2009
Primo Inserito (Stima)
7 luglio 2009
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
17 dicembre 2010
Ultimo aggiornamento inviato che soddisfa i criteri QC
16 dicembre 2010
Ultimo verificato
1 dicembre 2010
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie dell'apparato digerente
- Infezioni da virus a RNA
- Malattie virali
- Infezioni
- Infezioni a trasmissione ematica
- Malattie trasmissibili
- Malattie del fegato
- Flaviviridae Infezioni
- Epatite, virale, umana
- Epatite
- Epatite C
- Effetti fisiologici delle droghe
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Psicofarmaci
- Inibitori dell'assorbimento della serotonina
- Inibitori dell'assorbimento dei neurotrasmettitori
- Modulatori di trasporto a membrana
- Agenti serotoninergici
- Agenti antidepressivi
- Agenti antidepressivi, seconda generazione
- Citalopram
Altri numeri di identificazione dello studio
- CR016303
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Telaprevir; Escitalopram
-
Vertex Pharmaceuticals IncorporatedTibotec Pharmaceutical LimitedCompletatoEpatite CStati Uniti, Francia, Canada, Germania, Porto Rico
-
Tibotec BVBACompletato
-
Janssen Infectious Diseases BVBACompletatoInsufficienza epaticaGermania, Repubblica Ceca
-
Vertex Pharmaceuticals IncorporatedCompletatoEpatite CNuova Zelanda
-
Mitsubishi Tanabe Pharma CorporationVertex Pharmaceuticals IncorporatedCompletato
-
Santaris Pharma A/SCompletatoEpatite C | Epatite cronica CStati Uniti
-
MassBiologicsTerminato
-
Massachusetts General HospitalRitiratoEpatite virale CStati Uniti
-
Mitsubishi Tanabe Pharma CorporationVertex Pharmaceuticals IncorporatedCompletatoEpatite cronica CGiappone
-
GlaxoSmithKlineCompletatoTrombocitopeniaStati Uniti